Log inSign up
Reading a stock page
  • The tabs show the price chart, results, shareholding, events and news for this one company.
  • The Signal Score sums up trend, momentum and quality from past data. It is a description, not a forecast.
  • Every figure names its source. "Official" means it came from NSE or BSE filings.
  • Use the star to watch the stock, or Add to portfolio to record a trade.

Prices during market hours are delayed by up to 15 minutes. Nothing here is a recommendation to buy or sell.

« Dashboard

BAFNAPH ☆ BSE also on NSE

BAFNA PHARMACEUTICALS LTD. · code 532989 · INE878I01022 · Pharma & Healthcare · series T · Daily price history

470.25 -9.55 (-1.99%) close on 20 Nov 2026
Official NSE & BSE Auto-Sync: Checking Overview, Financials, Technicals, Shareholding & Events in the background...
78

ISA Signal Score: Strong setup

Buy candidate: research it further. Based on prices to 2026-11-20. Confidence 80%.

Trend100
Momentum70
52-week range94
Volume59
Risk59

Working for it

  • Price is above its 20-day average
  • Price is above its 50-day average
  • Price is above its 200-day average (long-term uptrend)
  • 50-day average is above the 200-day average
  • 50-day average is rising
  • RSI 59: healthy strength

Working against it

  • MACD is negative and weakening

Red flags

  • Thinly traded: average daily turnover is low, so entering or exiting can be hard

Measured reference levels (not forecasts): 20-day low 436.50, 52-week high 494.15, typical daily move 11.90, two typical moves below price 446.46.

A rule-based reading of price, volume and filed numbers. It is information, not investment advice, and it can be wrong. Do your own research.

At a glance

Five quick readings from results and prices. A starting point for your own research, not advice.
QualityAverageROE 13.7%, ROCE 15.6%
GrowthFastSales 19.2% a year over 7 years
ValuationExpensiveP/E 100.3 vs sector median 53.0
MomentumStrongAbove its 200-day average, beat NIFTY 50 by 176.7 points
RiskHighSwings 52% a year, fell up to 43% from a peak, beta 0.31

Smart Investor Tips: BAFNAPH

Constructive Setup (Trend + Fundamentals Aligned)

Actionable Insights & Positives

  • Confirmed uptrend: trading above both rising 50-day (Rs 412.79) and 200-day (Rs 233.30) averages.
  • Tip: Click the star button above to add this stock to your Watchlist and set a target "Buy below" alert price.

Risk Checks & Things to Verify

  • Premium valuation: P/E of 100.3x vs sector median 53.0x leaves less margin of safety if growth slows.

BSE Authentic Bhavcopy & Cross-Exchange Check No API Key

Runs authentic BSE price & volume verification (latest BSE Bhavcopy snapshot, split-adjusted 52W High/Low, 20/50/200 DMA alignment, and 20-day volume trend, plus cross-listed NSE MCP check when shared by ISIN).

Algorithmic Momentum Prediction & Optimal Entry PriceWAIT FOR PULLBACK (BUY ON DIPS) (Score 72/100)

Trend is strong (+13.9% above 50-DMA), so chasing at Rs 470.25 carries pullback risk. Better entry price: wait for a dip into Rs 427.80 – Rs 456.14 (near 20/50-DMA), with review stop at Rs 216.78 and target Rs 847.31.

Optimal Support areaTranche 1 (50%)Tranche 2 (50%)Risk level / ReviewLevel 1 (Swing)Level 2 (Breakout)Risk : Reward
Rs 427.80 – Rs 456.14
Ideal ~Rs 441.97
Rs 456.14 Rs 427.80 Rs 216.78
ATR 2.5%
Rs 847.31 Rs 1,117.54 1 : 1.8
RSI 60 · Vol 1.20x
1M 3M 6M 1Y 3Y ALL Investment checklist Download CSV 6M change +243.2% · high 504.00 · low 129.55 · max drawdown -23.7%

Live Candlestick & TradingView Chart (BAFNAPH)

MARKET CLOSED - EOD SNAPSHOT
Style:  Timeframe:  Overlays:

Key figures results FY26, price 20 Nov

P/E100.3sector median 53.0
P/B-price / book value
EPSRs 4.69earnings per share
Dividend yield-from saved dividend events
Debt to equity-borrowings / equity
Sales growth19.2%a year over 7 years
Profit growth-yearly, needs 2+ years
Operating margin13.7%net margin 7.4%

From the official NSE results filings, consolidated. P/E uses the last full year's EPS. See all years.

Company Debt, Borrowings & Cash Flow Health (Official FY26 Consolidated Filing)

Auto-extracted from official NSE/BSE XBRL Balance Sheet & Cash Flow statements (Rs Crore).

Adequate Debt & Cash Position · Score 55/100
Total Debt / Loans - Long + short-term loans
Cash & Bank Balances - Liquid cash & equivalents
Net Debt (Loans − Cash) - Net loan obligation
Debt to Equity & Interest Cover - Interest cover: 4.0x EBIT
Operating Cash Flow (OCF) - Cash generated from operations
Free Cash Flow (FCF) - OCF minus Capex

About BAFNA PHARMACEUTICALS

No company description saved yet. Use Profile below to read about this company.

Listed on BSE NSE

Market capNot available
First listed27 Feb 2020BSE not available · NSE 27 Feb 2020
Face valueRs 10
Book valueNot available
ROENot availableReturn on equity
ROCENot availableReturn on capital employed

NSE: listing date, face value

Profile completeness2 of 8Missing: description, industry, share count, book value, ROE, ROCE

Not checked yet.

Profile, History and Financial records open a web search for this company in a new tab.

Shareholding

Promoters and group 75.00% 0.00 pp, public 25.00%, as on 30 Sep 2026. Holder names and history

Day range470.25 to 485.00Open 485.00
52-week high504.00 -6.7% from high (13 Nov 2026)
52-week low95.00 +395.0% from low (16 Mar 2026)
Volume1,720 0.3x the 20-day average
RSI (14)59 neutral
Volatility (30d)28.1%annualised
95.00
504.00

Returns

1W-2.9%
1M+0.4%
3M+90.4%
6M+240.0%
1Y+175.2%
YTD+203.0%
3Y a year+74.9%
5Y a year+29.3%

Against the NIFTY 50

PeriodBAFNAPHNIFTY 50Difference
1M+0.4%+13.1% -12.7 pts
3M+90.4%+6.4% +84.0 pts
6M+240.0%+8.8% +231.2 pts
1Y+175.2%-1.5% +176.7 pts

Risk over the past year

Volatility52%high
Deepest fall-42.9%from a peak
Beta0.31moves less than the index
Best day+10.0%05 Jun 2026
Worst day-10.0%09 Jun 2026
Up days52%of sessions

Returns use closing prices. Bonus issues and splits are adjusted automatically when detected. Beta compares daily moves with the NIFTY 50 over 238 shared sessions.

AI analysis

Company turnover, products, risks and entry ideas, written by the AI provider you set up in Settings.

Open AI analysis

🛡 Forensic Financial Health: Piotroski F-Score & 3-Step DuPont ROE Decomposition

Institutional balance-sheet quality, earnings-to-cash conversion, and ROE driver breakdown from official XBRL filings.

Piotroski F-Score: 3 / 9 · Weak / Watch Balance Sheet
3-Step DuPont ROE Identity: Balanced Profitability & Efficiency
Net Margin: 7.4% × Asset Turnover: - × Equity Multiplier: - = ROE 13.7%
✓ Positive Net Profit (PAT > 0) Rs 11.1 Cr
⚠ Positive Operating Cash Flow (OCF > 0) N/A
⚠ High Cash Conversion (OCF >= 85% of PAT) N/A
⚠ Improving Return on Assets (ROA YoY) N/A
⚠ Conservative / Decreasing Debt-to-Equity Bank/Low
✓ Healthy Balance Sheet Asset Coverage Verified
⚠ Institutional Return on Equity (ROE >= 14%) 13.7%
✓ Stable / Expanding Profit Margin YoY 7.4% vs 4.8%
⚠ Asset Turnover Efficiency (Sales / Assets) N/A

Quarterly Results (Last 8 Quarters — QoQ & YoY Acceleration) Rs crore

Rs crore Jun 2024 Sep 2024 Dec 2024 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Sales / Revenue 33.340.333.234.635.538.342.226.6
Sales QoQ % -19.6%+21.1%-17.7%+4.3%+2.5%+8.0%+10.3%-37.1%
Operating Profit 0.863.803.065.675.454.275.312.80
Operating Margin (OPM %) 2.6%9.4%9.2%16.4%15.4%11.2%12.6%10.5%
Net Profit (PAT) -0.722.620.953.393.121.842.750.08
Profit QoQ % -149.3%+463.9%-63.7%+256.8%-8.0%-41.0%+49.5%-97.1%
Profit YoY % +66.2%+544.1%+132.3%+570.8%+19.1%+93.7%+189.5%-97.6%
Net Margin % -2.2%6.5%2.9%9.8%8.8%4.8%6.5%0.3%

Sales and profit Rs crore, consolidated

Sales growth+19.2%a year, 7Y
Profit growth-a year, 7Y
EPS growth-a year, 7Y
Avg ROE-24.4%5 years

Profit and loss

Rs croreFY19FY20FY23*FY24*FY26
Sales44.042.0115152151
Sales growth--4.5%+174.6%+32.2%-1.2%
Operating profit-13.01.0015.711.120.7
Operating margin-29.5%2.4%13.6%7.3%13.7%
Other income1.00-22.03.273.52-
Interest2.0002.042.293.66
Depreciation3.003.005.335.006.07
Profit before tax-17.0-24.011.67.3511.0
Tax rate--2.4%0.0%-1.2%
Net profit-18.0-24.011.37.3511.1
Profit growth----35.2%+51.0%
Net margin-40.9%-57.1%9.8%4.8%7.4%
EPS (Rs)-7.98-104.544.863.114.69

Balance sheet

Rs croreFY19FY20FY23*FY24*FY26
Equity (net worth)19.051.073.580.8-
Borrowings46.03.0022.924.4-
Cash--7.811.40-
Total assets11971.0130148-
Debt to equity2.42x0.06x0.31x0.30x-

Debt, Loans, Cash Flow & Working Capital

Rs croreFY19FY20FY23*FY24*FY26
Operating Cash Flow (OCF)-2.00-34.04.959.48-
Capital Expenditure (Capex)--6.7215.6-
Free Cash Flow (FCF = OCF - Capex)---1.77-6.10-
OCF / Net Profit Conversion--0.44x1.29x-
Total Borrowings / Loans46.03.0022.924.4-
Cash & Bank Balances--7.811.40-
Trade Receivables (Cr)--41.245.4-
Receivable Days--130.21x108.66x-
Inventories (Cr)--22.229.6-
Inventory Days--70.31x70.96x-

Returns on capital

Rs croreFY19FY20FY23*FY24*FY26
ROE-94.7%-68.6%18.2%9.5%13.7%
ROCE-23.1%-40.3%19.9%10.9%15.6%
Interest cover-7.50x-6.70x4.21x4.00x

Read from the official annual results filed with NSE (XBRL), consolidated figures; years marked * are on the other basis because only that file was readable. ROE uses average equity of the year and the year before when both are saved, ROCE uses profit before interest and tax over total assets less current liabilities. EPS is per today's share. Check the annual report before investing.

Compared with its sector Pharma & Healthcare

StockPriceDay1 yearMkt cap (Cr)P/EP/BROENet margin
LAURUSLABSLaurus Labs Limited 2,295.00 -0.3% - 123,689 139.4 23.3 16.8% 13.1%
ZYDUSLIFEZydus Lifesciences Limited 1,195.05 -0.4% - 120,222 31.3 6.1 0.6% 0.6%
GLENMARKGLENMARK PHARMACEUTICALS LTD. 2,648.00 +1.0% - 74,724 - 9.5 -19.1% -12.7%
FORTISFORTIS HEALTHCARE LTD. 825.00 +2.0% - 62,284 59.8 - 7.8% 11.7%
GLANDGland Pharma Limited 3,331.35 +1.2% - 54,871 53.4 - 8.9% 16.0%
GLAXOGLAXOSMITHKLINE PHARMACEUTICAL 2,732.50 +0.7% - 46,291 78.5 26.0 33.2% 17.1%
EMCUREEmcure Pharmaceuticals Limited 2,336.05 -0.4% - 44,317 47.9 9.0 19.0% 10.2%
SAILIFESai Life Sciences Limited 1,800.35 +0.7% - 38,243 109.2 15.4 14.0% 15.9%
WOCKPHARMAWOCKHARDT LTD. 2,183.10 -0.2% - 33,620 166.4 6.8 4.3% 6.4%
GRANULESGRANULES INDIA LTD. 823.70 +2.4% - 19,964 34.3 3.9 11.7% 11.1%
ERISEris Lifesciences Limited 1,319.50 -0.6% - 17,949 45.8 6.9 15.2% 19.5%
ALIVUSALIVUS LIFE SCIENCES LIMITED 1,434.15 -1.1% - 17,576 37.3 7.5 20.2% 20.6%
Sector median- 53.09.012.8%

The 12 largest of 80 stocks in this sector on BSE, by market cap where known and traded value otherwise. Valuation shows for stocks whose results this site has read; it fills in as people open more stock pages. Prices from 20 Nov 2026.

Today: 15 minute chart and signal

Opens when you view this tab.

Analysis and next-session reading

Opens when you view this tab.

Complete analysis report Financials, shareholding, events, risks and a data reliability score.

Signals

Price is above its 50-day average 20-day average is above the 50-day (short-term uptrend) Price is above its 200-day average (long-term uptrend) RSI 59: neutral

Simple rules applied to end-of-day prices. They describe what the chart is doing and are not advice to buy or sell.

When is a good price? from this stock's own price history

The price is in the upper quarter of its 1-year range and is lower than it was on 4% of days in the past year.

Support (prices below today's)

20-day low427.80-9.0%
50-day average412.79-12.2%
60-day low265.95-43.4%
200-day average233.30-50.4%
52-week low95.00-79.8%

Resistance (prices above today's)

20-day high504.00+7.2%
60-day high504.00+7.2%
52-week high504.00+7.2%

Zones buyers often watch

Lower quarter of the 1-year range 95.00 to 197.25 Historically the cheapest part of the past year.
Pullback of 10% to 20% from the high 403.20 to 453.60 A common area for dips inside an uptrend.
Around the 200-day average 226.30 to 240.29 Long-term trend line, often watched as support.

Deepest fall from a peak in the past year: -42.9%. Currently -4.8% below its latest peak. Levels are from history and do not predict where the price will go.

Moving averages and momentum

IndicatorValueReading
20-day average462.99 Price is 1.6% above
50-day average412.79 Price is 13.9% above
200-day average233.30 Price is 101.6% above
RSI (14)59Neutral
MACD (12, 26, 9)17.72Below its signal line (momentum fading)
Volatility (30d)28.1%Medium yearly swings

Support and resistance

R2489.92
R1480.08
Pivot475.17
S1465.33
S2460.42

Classic pivot levels from the latest session's high, low and close. Prices often pause near them, but they are only reference points.

DateOpenHighLow CloseChangeVolume
2026-11-20 485.00 485.00 470.25 470.25 -1.99% 1,720
2026-11-19 486.50 486.50 479.80 479.80 +0.59% 3,739
2026-11-18 485.00 485.00 473.95 477.00 -0.62% 512
2026-11-17 484.00 484.00 480.00 480.00 +1.05% 6,313
2026-11-16 484.30 485.00 475.00 475.00 -1.92% 8,893
2026-11-13 504.00 504.00 484.30 484.30 -1.99% 31,428
2026-11-12 494.15 494.15 494.15 494.15 +1.99% 7,824
2026-11-11 486.50 486.50 484.50 484.50 +1.57% 10,380
2026-11-09 477.50 477.50 472.80 477.00 +1.89% 1,345
2026-11-06 463.00 463.00 452.10 459.00 +1.08% 3,538
2026-11-05 454.10 454.10 450.00 454.10 +2.00% 846
2026-11-04 427.80 445.20 427.80 445.20 +1.99% 1,475
2026-11-03 430.20 436.50 430.20 436.50 -0.56% 1,423
2026-11-02 438.95 439.00 438.95 438.95 -2.00% 1,318
2026-10-30 455.00 455.00 447.90 447.90 -1.99% 2,056
2026-10-29 460.60 460.60 457.00 457.00 -0.36% 3,715
2026-10-28 458.65 458.65 451.00 458.65 +1.99% 13,594
2026-10-27 449.70 449.70 449.70 449.70 +2.00% 12,235
2026-10-26 440.90 440.90 440.90 440.90 -1.99% 50
2026-10-23 449.85 449.85 449.85 449.85 -1.99% 6
2026-10-22 459.00 459.00 459.00 459.00 -2.00% 2,340
2026-10-21 487.45 487.45 468.35 468.35 -2.00% 8,826
2026-10-19 469.80 477.90 469.80 477.90 +1.97% 7,544
2026-10-16 465.00 468.65 460.00 468.65 +1.99% 72,951
2026-10-15 459.95 459.95 459.50 459.50 +1.90% 2,510
2026-10-14 450.95 450.95 450.95 450.95 +1.99% 28,380
2026-10-13 442.15 442.15 442.15 442.15 +2.00% 4,036
2026-10-12 433.50 433.50 433.50 433.50 +2.00% 2,115
2026-10-09 425.00 425.00 425.00 425.00 +1.99% 4,036
2026-10-08 416.70 416.70 416.70 416.70 +1.99% 7,129
2026-10-07 408.55 408.55 408.55 408.55 +2.00% 5,006
2026-10-06 400.55 400.55 400.55 400.55 +2.00% 5,386
2026-10-05 392.70 392.70 392.70 392.70 +2.00% 4,129
2026-10-01 385.25 385.25 385.00 385.00 +1.93% 4,913
2026-09-30 377.70 377.70 377.70 377.70 +2.00% 2,106
2026-09-29 370.30 370.30 370.30 370.30 +2.00% 2,995
2026-09-28 363.05 363.05 363.05 363.05 +1.99% 7,178
2026-09-25 355.95 355.95 355.95 355.95 +1.99% 21,504
2026-09-24 349.00 349.00 349.00 349.00 +1.99% 5,523
2026-09-23 342.20 342.20 342.00 342.20 +2.00% 3,390
2026-09-22 335.50 335.50 335.50 335.50 +1.99% 2,657
2026-09-21 328.95 328.95 328.95 328.95 +2.00% 4,584
2026-09-18 322.50 322.50 322.50 322.50 +1.99% 805
2026-09-17 312.00 316.20 310.00 316.20 +2.00% 3,225
2026-09-16 307.45 310.00 307.45 310.00 +0.34% 334
2026-09-15 303.00 309.05 303.00 308.95 +1.96% 2,401
2026-09-11 303.00 303.00 297.50 303.00 +1.99% 413
2026-09-10 296.40 297.10 296.40 297.10 -1.75% 1,012
2026-09-09 303.00 303.00 302.40 302.40 -1.99% 177
2026-09-08 308.55 308.55 308.55 308.55 +2.00% 4,202
2026-09-07 291.80 302.50 291.80 302.50 +1.99% 2,757
2026-09-04 308.50 308.50 296.50 296.60 -1.97% 224
2026-09-03 302.55 302.55 302.55 302.55 -1.99% 509
2026-09-02 308.70 308.70 308.70 308.70 -2.00% 2,585
2026-09-01 305.00 318.00 300.90 315.00 +3.45% 2,743
2026-08-31 302.00 304.90 300.00 304.50 +4.86% 4,300
2026-08-28 285.00 290.40 266.50 290.40 +4.99% 1,830
2026-08-27 288.90 290.00 271.65 276.60 -3.25% 3,496
2026-08-26 285.90 285.90 284.85 285.90 +4.99% 19,215
2026-08-25 269.00 272.30 265.95 272.30 +4.99% 5,980
2026-08-24 252.00 259.35 252.00 259.35 +5.00% 9,744
2026-08-21 237.40 247.00 237.40 247.00 +1.98% 3,565
2026-08-20 242.20 242.20 242.20 242.20 -1.98% 84
2026-08-19 247.10 247.10 247.10 247.10 -1.98% 1,732
2026-08-18 252.10 252.10 252.10 252.10 -1.98% 9
2026-08-17 257.20 257.20 257.20 257.20 -1.98% 400
2026-08-14 262.40 262.40 262.40 262.40 -2.00% 1
2026-08-13 267.75 267.75 267.75 267.75 -1.99% 58
2026-08-12 273.20 273.20 273.20 273.20 -1.99% 94,084
2026-08-11 278.75 278.75 278.75 278.75 -1.99% 26
2026-08-10 296.00 296.00 284.40 284.40 -2.00% 13,751
2026-08-07 284.55 290.20 284.55 290.20 +1.99% 1,388
2026-08-06 283.00 288.65 283.00 284.55 +0.55% 3,141
2026-08-05 284.15 284.15 283.00 283.00 +1.58% 7,418
2026-08-04 278.00 278.60 278.00 278.60 +2.00% 7,656
2026-08-03 273.15 273.15 273.15 273.15 +2.00% 3,793
2026-07-31 269.20 269.20 263.00 267.80 +1.46% 4,352
2026-07-30 263.95 263.95 263.95 263.95 +1.99% 6,078
2026-07-29 258.80 258.80 258.80 258.80 +1.99% 3,391
2026-07-28 248.80 253.75 248.80 253.75 +1.99% 4,206
2026-07-27 243.80 249.00 243.80 248.80 +1.55% 3,275
2026-07-24 238.20 246.95 238.00 245.00 +1.07% 1,439
2026-07-23 242.40 242.40 242.40 242.40 +2.00% 2,025
2026-07-22 237.65 237.65 237.65 237.65 +2.00% 156
2026-07-21 233.55 233.55 233.00 233.00 +1.75% 595
2026-07-20 229.05 229.05 225.00 229.00 -0.02% 2,996
2026-07-17 229.05 229.05 229.05 229.05 +1.98% 5,404
2026-07-16 224.60 224.60 224.60 224.60 +2.00% 1,469
2026-07-15 220.20 220.20 220.20 220.20 +1.99% 2,771
2026-07-14 215.90 215.90 215.90 215.90 +1.98% 8,384
2026-07-13 211.70 211.70 211.00 211.70 +2.00% 726
2026-07-10 199.45 207.55 199.45 207.55 +1.99% 1,998
2026-07-09 203.50 203.50 203.50 203.50 -2.00% 1,000
2026-07-08 207.65 207.65 207.65 207.65 -1.98% 134
2026-07-07 211.85 211.85 211.85 211.85 -1.99% 37
2026-07-06 216.15 216.15 216.15 216.15 -2.00% 323
2026-07-03 220.90 221.00 220.55 220.55 -2.00% 9,298
2026-07-02 234.15 234.15 225.05 225.05 -1.98% 12,360
2026-07-01 224.00 229.60 224.00 229.60 +4.98% 5,045
2026-06-30 210.40 218.70 210.40 218.70 +4.99% 21,135
2026-06-29 208.40 208.40 200.00 208.30 +4.94% 21,959
2026-06-25 198.50 198.50 198.50 198.50 +5.00% 5,786
2026-06-24 183.00 189.05 183.00 189.05 +5.00% 12,608
2026-06-23 180.00 180.05 172.10 180.05 +4.99% 24,925
2026-06-22 165.95 171.50 163.35 171.50 +4.99% 6,933
2026-06-19 155.75 164.30 155.75 163.35 +4.38% 16,099
2026-06-18 158.75 158.75 150.30 156.50 -0.70% 4,947
2026-06-17 145.10 157.60 145.10 157.60 +5.00% 5,300
2026-06-16 150.60 150.60 150.10 150.10 -4.97% 1,211
2026-06-15 167.90 167.90 157.95 157.95 -4.99% 9,295
2026-06-12 168.25 174.00 166.25 166.25 -4.97% 6,653
2026-06-11 159.75 176.55 159.75 174.95 +4.04% 21,791
2026-06-10 168.15 168.15 168.15 168.15 -4.97% 405
2026-06-09 208.00 216.25 176.95 176.95 -9.99% 49,886
2026-06-08 188.00 196.60 188.00 196.60 +9.99% 18,118
2026-06-05 173.00 178.75 165.00 178.75 +10.00% 6,079
2026-06-04 162.50 162.50 162.50 162.50 +4.97% 1,605
2026-06-03 153.80 154.80 153.80 154.80 +4.98% 3,852
2026-06-02 146.85 147.45 146.85 147.45 +4.98% 2,448
2026-06-01 134.00 140.70 134.00 140.45 +4.81% 1,321
2026-05-29 134.30 134.80 129.85 134.00 -0.37% 201
2026-05-27 135.80 136.00 134.50 134.50 +3.82% 94
2026-05-26 130.55 133.00 129.55 129.55 -4.95% 270
2026-05-25 133.55 136.30 133.50 136.30 -1.45% 412
2026-05-22 138.30 138.30 138.30 138.30 +0.00% 1
2026-05-21 138.00 138.35 138.00 138.30 -0.07% 1,113
2026-05-20 138.40 138.40 138.40 138.40 +1.02% 100
2026-05-18 137.00 137.00 137.00 137.00 -0.72% 141

News from the last 15 days More

Shareholding pattern

Up to dateNSE listingChecks passed

Quarter ended 30 Sep 2026, filed 21 Oct 2026. Latest filing is for the expected quarter (Sep 2026). Company: Bafna Pharmaceuticals Limited, ISIN INE878I01022.

Promoters and group
75.00%
0.00 pp vs Jun 2026
Public (all, Category B)
25.00%
0.00 pp vs Jun 2026

Foreign, domestic institution and mutual fund lines need the filing file for the period. An admin can load them under Admin > Shareholding tracker.

Ownership split

Trend

Latest quarter compared

CategoryPrevious (Jun 26)Latest (Sep 26)Change (pp)Change in sharesYear earlier (pp)What it may mean
Promoters and group75.00%75.00%0.00 pp-0.00 ppNo material change.
Public (all, Category B)25.00%25.00%0.00 pp-0.00 ppNo material change.

Change is in percentage points (latest percent minus previous percent), not a relative change. Mutual funds and insurers are part of domestic institutions and are never added to it. Only comparable quarters (1 to 6 months apart; about a year for the year-earlier column) are compared.

Insights and risk alerts

No rule was triggered by the data in the database. That is not a clean bill of health: the rules look only at reported holdings.

These alerts describe reported ownership. They are not buy or sell advice. Judge the company with its results, debt, valuation and announcements.

Who holds the shares

Largest holders named in the Sep 2026 filing.

NameTypeShares% of companyLocked-in shares
Srjr Lifesciences LLPBodies Corporate1,76,40,01674.57% -
Cullinan Opportunities Fund Vcc-Cullinan Opportunities Incorporated Vcc Sub Fund 1Institutions Foreign Portfolio Investor One7,60,0593.21% -
M7 Global Fund Pcc-Cell Dewcap FundInstitutions Foreign Portfolio Investor One7,37,1583.12% -
Zeal Global Opportunities FundInstitutions Foreign Portfolio Investor One7,12,5863.01% -
Alpana MundraResident Individual Shareholders Holding Nominal Share Capital In Excess Of Rs Two Lakh6,46,3502.73% -
Monarch Networth Finserve Private LimitedBodies Corporate3,18,2541.35% -

Quarter by quarter

Quarter endedPromotersChangePublicChangeFiledSource
Sep 202675.00%0.00 pp25.00%0.00 pp21 Oct 2026
Jun 202675.00%0.00 pp25.00%0.00 pp20 Jul 2026
Mar 202675.00%0.00 pp25.00%0.00 pp21 Apr 2026
Dec 202575.00%0.00 pp25.00%0.00 pp19 Jan 2026
Sep 202575.00%0.00 pp25.00%0.00 pp16 Oct 2025
Jun 202575.00%0.00 pp25.00%0.00 pp17 Jul 2025
Mar 202575.00%-13.30 pp25.00%+13.30 pp16 Apr 2025NSE
Dec 202488.30%0.00 pp11.70%0.00 pp10 Jan 2025NSE
Sep 202488.30%0.00 pp11.70%0.00 pp19 Oct 2024NSE
Jun 2024 revised88.30%0.00 pp11.70%0.00 pp13 Jul 2024NSE
Mar 2024 revised88.30%-0.13 pp11.70%+0.13 pp21 Apr 2024NSE
Dec 2023 revised88.43%-0.31 pp11.57%+0.31 pp10 Jan 2024NSE
Sep 2023 revised88.74%-1.26 pp11.26%+1.26 pp13 Oct 2023NSE
Jun 2023 revised90.00%0.00 pp10.00%0.00 pp20 Jul 2023NSE
Mar 2023 revised90.00%-0.02 pp10.00%+0.02 pp11 Apr 2023NSE
Dec 2022 revised90.02%+0.02 pp9.98%-0.02 pp13 Jan 2023NSE
Sep 2022 revised90.00%-0.12 pp10.00%+0.12 pp21 Oct 2022NSE
Jun 202290.12%-0.30 pp9.88%+0.30 pp12 Jul 2022NSE
Mar 2022 revised90.42%0.00 pp9.58%0.00 pp11 Apr 2022NSE
Dec 202190.42%+0.02 pp9.58%-0.02 pp20 Jan 2022NSE
Sep 202190.40%-9.60%-18 Oct 2021NSE
Shareholding details

Loading...

Events

Not checked yet

BSE events come from the BSE corporate actions file, which an admin uploads. There is no automatic BSE fetch. Nothing has been imported for this stock yet.

No events saved for this stock yet.

Fetched from NSE automatically and saved on this site, so past events stay available. Ex date is the first day the stock trades without the benefit; a bonus or split is applied to old prices on its own from that day. Confirm on the exchange website before acting.

ISA shows information and signals worked out from past prices and company filings. They are not recommendations to buy, sell or hold any security, and ISA is not a SEBI-registered investment adviser or research analyst. Prices may be delayed. Check with a registered adviser before you invest.